Any current/future new fundraising through debt or equity?

Quick Heal Technologies currently has no debt and has a strong cash position with over ₹182 crores in cash and cash equivalents. The company is focused on profitable growth and maintaining financial strength. While they are open to potential investments aligned with their growth strategy, there are no specific plans announced currently for new fundraising through debt or equity. Management indicated they will consider acquisitions or investments if they fit the strategic growth plans and when the opportunity arises.

Any current/future capex/capital investment/strategic investment?

The company is currently in an investment mode, particularly focusing on building a strong product foundation and enterprise cybersecurity stack. Significant investments have been made in research and development over the last 3-4 years to deliver multiple solutions simultaneously. R&D investments will continue, with a proper roadmap and quarterly release cycle planned for all solutions. There are focused investments in building and reenergizing the sales organization for mid-market and large enterprises. The company has a strong balance sheet with over ₹182 crores in cash and cash equivalents

Future growth expectations in sales/revenue/volumes?

The company anticipates continued growth in the enterprise security segment, which is expanding faster than the consumer security market. Enterprise business has grown from 20% in FY21 to around 40% currently, and this upward trend is expected to continue. Investments in sales augmentation, particularly for mid-market and large enterprises, will support scaling efforts. Quick Heal aims for profitable growth with a long-term perspective, focusing on strengthening product offerings and expanding channel partnerships. New products and features (e.g., Quick Heal version 24, cloud-based Meta Protec

Future growth expectations in earnings/operating earnings/profits/EPS?

Quick Heal is focused on **profitable growth** with a long-term view rather than short-term absolute numbers. The company expects **margin improvement** as scale increases and ongoing heavy investments start stabilizing. It plans to continue **doubling down on R&D and sales investments**, fueling product innovation and sales augmentation. Enterprise business growth is anticipated to be **much faster than consumer market**, increasing its share in revenues. Management targets **scaling and consolidating enterprise solutions**, expecting these efforts to start bearing fruit in time. The consumer

Quick Heal Technologies LtdQ2 FY24IT - Software

Quick Heal Technologies Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹136.79Market Cap: ₹743 CrSector: IT - Software

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company anticipates continued growth in the enterprise security segment, which is expanding faster than the consumer security market.
Enterprise business has grown from 20% in FY21 to around 40% currently, and this upward trend is expected to continue.
Investments in sales augmentation, particularly for mid-market and large enterprises, will support scaling efforts.
Quick Heal aims for profitable growth with a long-term perspective, focusing on strengthening product offerings and expanding channel partnerships.
New products and features (e.g., Quick Heal version 24, cloud-based Meta Protect) are expected to drive adoption and market traction.
Consumer antivirus (AV) penetration in India is only 20%, indicating significant latent potential compared to 50% in developed countries.
Expansion in international markets such as Africa, the Middle East, and Europe is ongoing but currently tactical; global growth plans exist for the future.
Focus remains on leveraging "Make in India" advantage and enhancing brand presence via marketing and partnerships.

Margin guidance

Category 3

Quick Heal is focused on profitable growth with a long-term view rather than short-term absolute numbers.
The company expects margin improvement as scale increases and ongoing heavy investments start stabilizing.
It plans to continue doubling down on R&D and sales investments, fueling product innovation and sales augmentation.
Enterprise business growth is anticipated to be much faster than consumer market, increasing its share in revenues.
Management targets scaling and consolidating enterprise solutions, expecting these efforts to start bearing fruit in time.
The consumer business is regaining momentum after headwinds, with potential for growth due to low AV penetration in India (~20%).
Quick Heal aims to expand internationally and tap into new markets like Africa and the Middle East.
The company will maintain its dividend policy, but currently no buyback plans.
Financial discipline emphasized: zero debt, strong cash balance, enabling strategic investments.

See what Quick Heal Technologies Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Quick Heal Technologies currently has no debt and has a strong cash position with over ₹182 crores in cash and cash equivalents.
The company is focused on profitable growth and maintaining financial strength.
While they are open to potential investments aligned with their growth strategy, there are no specific plans announced currently for new fundraising through debt or equity.
Management indicated they will consider acquisitions or investments if they fit the strategic growth plans and when the opportunity arises.

Order book

The provided transcript from Quick Heal Technologies Limited's Q2 FY24 earnings call does not explicitly mention details regarding the current or expected orderbook or pending orders. However, relevant points about business traction and customer onboarding include: - Onboarded 82 new enterprise customers in the first half of FY24 for new products. - Enterprise business now represents 40% of total revenue, growing at a CAGR of 21% over the last three years. - The company is in early stages of enterprise solution releases, focusing on consolidation and feedback to scale. - Strong focus on building partnerships with system integrators, distributors, and channel partners to expand enterprise reach. - No explicit comment on specific order backlog or pending orders was made during the call. Thus, while customer additions and growth trajectory are discussed, there is no direct disclosure of orderbook or pending orders.

See what Quick Heal Technologies Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is currently in an investment mode, particularly focusing on building a strong product foundation and enterprise cybersecurity stack.
Significant investments have been made in research and development over the last 3-4 years to deliver multiple solutions simultaneously.
R&D investments will continue, with a proper roadmap and quarterly release cycle planned for all solutions.
There are focused investments in building and reenergizing the sales organization for mid-market and large enterprises.
The company has a strong balance sheet with over ₹182 crores in cash and cash equivalents and zero debt.
While no specific immediate capital expenditure plans were detailed, the company remains open to strategic investments or acquisitions aligned with its growth strategy.
The approach prioritizes profitable growth and long-term scaling, with investments guided by strategic fit and growth potential.

Track Quick Heal Technologies Ltd — get its next earnings analysis in your feed

How does Quick Heal Technologies Ltd rank vs peers in IT - Software?

Pro feature

ThisQuick Heal Technologies Ltd

Rev 3Mar 3

See where Quick Heal Technologies Ltd sits in IT - SoftwareSee which companies these are, and every other name in the sector.Open rankings

How does Quick Heal Technologies Ltd rank in IT - Software?

Compare Quick Heal Technologies Ltd against every IT - Software company (Q2 FY24) on revenue, margins and earnings-call signals.

View IT - Software leaderboard →

What Quick Heal Technologies Ltd's management said in earlier quarters

Others in IT - Software this season

3i Infotech Ltd (Q2 FY27)
Q2 FY27 consolidated operating revenue: ₹182.0 crore, up 4.1% YoY from ₹174.9 crore in Q2 FY26. Key investor presentation takeaways from 3i Infotech Ltd's Q2 FY
InfoBeans Tech. (Q2 FY27)
3,780 Lakhs increase, approximately 30.1% growth . Key investor presentation takeaways from InfoBeans Technologies Ltd's Q2 FY27 investor presentation — and how
Hexaware Technologies Ltd (Q2 FY27)
USD 411.9 million (+4.3% YoY, +1.6% QoQ) . Key investor presentation takeaways from Hexaware Technologies Ltd's Q2 FY27 investor presentation — and how it ranks
Zensar Technologies Ltd (Q2 FY27)
Year-on-year revenue growth: 2.0% in constant currency, 11.5% in INR terms . Key investor presentation takeaways from Zensar Technologies Ltd's Q2 FY27 investor

Compare:vs TCS vs Infosys Ltd vs HCL Technologies

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Quick Heal Technologies Ltd Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Quick Heal Technologies Ltd rank in IT - Software?

Continue your research

What Quick Heal Technologies Ltd's management said in earlier quarters

Others in IT - Software this season